Dossier assessment
Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with moderate to severe plaque psoriasis for whom systemic treatment is an option
In case of contraindication, intolerance or inadequate response to other systemic treatments including ciclosporin, methotrexate or PUVA: hint of non-quantifiable added benefit. Other patients: lesser benefit or added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-03-01 A G-BA decision was published.
Project details
- Project no.
- A17-42
- Commission
- Commission awarded on 01.09.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.